Shanghai Pharmaceuticals: Approval for production of SGLT2 metformin sustained-release tablets.

Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has received a Drug Registration Certificate from the National Medical Products Administration for its Sitagliptin and Metformin Sustained-Release Tablets. The drug has been approved for production. Sitagliptin and Metformin Sustained-Release Tablets are used for adult type 2 diabetes patients who are receiving combination treatment with Sitagliptin and Metformin Sustained-Release Tablets. The drug was originally developed by Merck Sharp & Dohme and was first marketed in the United States in 2012.